Theravance Biopharma (TBPH) Cash & Equivalents (2014 - 2026)

Theravance Biopharma (TBPH) has 13 years of Cash & Equivalents data on file, last reported at $288.1 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $288.1 million, up 160.46% year-over-year; the trailing twelve-month figure through Mar 2026 was $288.1 million (up 160.46% YoY), and the FY2025 annual result was $167.8 million, up 343.97% from the prior year.
• Cash & Equivalents improved to $288.1 million in Q1 2026 per TBPH's latest filing, from $167.8 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $418.5 million in Q3 2022 and troughed at $23.4 million in Q3 2024.
• A 5-year average of $146.3 million and a median of $105.6 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents plunged 86.74% in 2023, then soared 647.6% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $298.2 million in 2022, then sank by 86.74% to $39.5 million in 2023, then decreased by 4.42% to $37.8 million in 2024, then soared by 343.97% to $167.8 million in 2025, then jumped by 71.69% to $288.1 million in 2026.
• Business Quant data shows TBPH's Cash & Equivalents at $288.1 million in Q1 2026, $167.8 million in Q4 2025, and $174.8 million in Q3 2025.